Dr. Matthew F. Heil has served as Curemark’s Chief Scientific Officer since 2008. Dr. Heil is responsible for the oversight and direction of all scientific programs as well as drug formulation and manufacturing.
While a member of the Faculty of Medicine at New York Medical College (NYMC), Dr. Heil became a Principal Investigator conducting research on growth regulation in leukemia. He also served on NYMC’s Experimental Bone Marrow Transplant Team investigating new methodologies for allowing bone marrow transplants for patients who did not have a matching graft donor.
As a Senior Partner of both the Delphi Group and BioInnovators Consulting, Dr. Heil worked closely with senior management teams at biotechnology and pharmaceutical companies on product licensing, product valuation, technical due diligence and other aspects of research and product development .
Dr. Heil holds a Bachelor of Science in Biology from Loyola University in Chicago, a Master’s Degree from the University of Toronto and a Doctorate in Immunology from Syracuse University.